title: The economic impact of Medicare Part D on congestive heart failure.
abstract: Medicare Part D has had important implications for patient outcomes and treatment costs among beneficiaries with congestive heart failure (CHF). This study finds that improved medication adherence associated with expansion of drug coverage under Part D led to nearly $2.6 billion in reductions in medical expenditures annually among beneficiaries diagnosed with CHF and without prior comprehensive drug coverage, of which over $2.3 billion was savings to Medicare. Further improvements in adherence could potentially save Medicare another $1.9 billion annually, generating upwards of $22.4 billion in federal savings over 10 years.
authors.affiliation: IHS Healthcare & Pharma, Washington, DC, USA. tim.dall@ihs.com
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Dall
authors.forename: Tericke D
authors.initials: TD
authors.lastname: Blanchard
authors.forename: Paul D
authors.initials: PD
authors.lastname: Gallo
authors.forename: April P
authors.initials: AP
authors.lastname: Semilla
mesh_terms: D002316:Cardiotonic Agents / Q000191:economics / Q000627:therapeutic use; D017046:Cost Savings / Q000191:economics; D005102:Health Expenditures / Q000706:statistics & numerical data; D006333:Heart Failure / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D054524:Medicare Part D / Q000191:economics*; D014481:United States; D016903:Drug Monitoring
chemical_list: D002316:Cardiotonic Agents